Tarsus Pharmaceuticals Inc

TARS

Equity

ISIN null / Valor 57410241

NASDAQ (2025-11-19)

USD 77.11+0.18%

Tarsus Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Tarsus Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative treatments for diseases with significant unmet medical needs. The company has gained recognition for its FDA-approved product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, which is the first treatment specifically approved for Demodex blepharitis, a condition affecting millions of patients. Tarsus is committed to expanding its pipeline with a focus on addressing large-scale diseases that currently have limited treatment options, thereby aiming to improve patient outcomes across various therapeutic areas.

Summarized from source with an LLMView SourceSector: Technology

Record Net Product Sales

Net product sales reached $102.7 million, a 152% increase year-over-year, with approximately 91,000 bottles of XDEMVY delivered to patients.

Successful Direct-To-Consumer Campaign

The company’s direct-to-consumer advertising campaign significantly boosted prescription growth, expanding the patient base and increasing the number of Eye Care Professionals prescribing XDEMVY by over 30% since early 2025.

Pipeline Advancements and Global Expansion

Tarsus remains on track with its clinical pipeline, planning Phase 2 studies for TP-04 and TP-05, and progressing with regulatory meetings in Japan and potential European approval for a preservative-free formulation of XDEMVY by 2027.

Improved Financial Performance

For Q2 2025, Tarsus reported a net loss of $20.3 million, reduced from $33.3 million in Q2 2024, and maintained a strong cash position of $381.1 million as of June 30, 2025.

Summarized from source with an LLMView Source

Key figures

64.4%1Y

359%3Y

230%5Y

Performance

50.2%1Y

58.6%3Y

66.0%5Y

Volatility